Suven Life Sciences Limited announced major corporate developments following its board meeting held on January 29, 2026, including equity share allotment and key management personnel changes. The pharmaceutical company's board approved significant capital restructuring alongside leadership transitions in compliance with regulatory requirements.

Equity Share Allotment Through Warrant Conversion

The board approved the conversion of 44,77,612 fully paid warrants into equity shares, resulting in the allotment of an equal number of equity shares to non-promoter entities. The shares were issued at Rs 134 per share on a preferential basis, generating total proceeds of Rs 60,00,00,008.

The allotment was conducted in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, with the company receiving 100% consideration from the allottees. Each equity share carries a face value of Rs 1 with a premium of Rs 133 per share.

Impact on Share Capital Structure

Following the preferential allotment, Suven Life Sciences' paid-up equity share capital witnessed substantial expansion. The conversion resulted in a notable increase in the company's equity base.

Company Secretary Resignation

Mr. Shrenik Soni tendered his resignation from the position of Company Secretary and Compliance Officer, effective from close of business hours on January 30, 2026. The resignation was submitted on November 11, 2025, citing pursuit of alternate career opportunities as the primary reason, with no other material factors involved.

The board accepted the resignation and recorded appreciation for Mr. Soni's services during his tenure. His departure necessitated immediate succession planning to ensure continuity in statutory compliance functions.

New Company Secretary Appointment

Ms. Sangeetha Laxmi Kandari has been appointed as the new Company Secretary and Compliance Officer, taking charge from February 2, 2026. The appointment was made based on recommendations from the Nomination and Remuneration Committee.

Ms. Kandari brings extensive experience in corporate, secretarial, and compliance functions, having previously worked with Shilpa Biocare Pvt. Ltd, Avra Laboratories Pvt. Ltd, and Prasad Media Corporation Pvt. Ltd. She will also serve as Compliance Officer under SEBI (LODR) Regulations and SEBI (PIT) Regulations, 2015.

Board Meeting Details

The board meeting commenced at 11:30 AM IST and concluded at 12:40 PM IST on January 29, 2026. All decisions were made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with appropriate disclosures submitted to stock exchanges.

Suven Life Sciences has reported its Q3 consolidated financial results, revealing a substantial widening of net losses compared to the same period in the previous fiscal year. The pharmaceutical company's financial performance during the quarter reflects significant operational challenges.

Financial Performance Overview

The company's Q3 consolidated results show a marked deterioration in profitability metrics. The net loss figures demonstrate the extent of financial pressure faced by the organization during this reporting period.

Year-over-Year Comparison

The year-over-year analysis reveals the magnitude of the company's financial challenges. Suven Life Sciences' consolidated net loss of ₹1.02 billion in Q3 represents a significant increase from the ₹391.2 million loss recorded in the corresponding quarter of the previous year.

This substantial widening of losses indicates that the company faced considerable operational headwinds during the quarter. The approximately 161% increase in net losses on a year-over-year basis highlights the severity of the financial impact experienced by the pharmaceutical company.

Impact Assessment

The reported financial results underscore the challenging environment in which Suven Life Sciences operated during Q3. The more than doubling of net losses compared to the previous year's corresponding quarter reflects the significant financial pressures affecting the company's operations and profitability during this period.